Related Experiment Video
Updated: Jul 2, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Prevention of atrial fibrillation in hypertension
Tonje A Aksnes1, Arnljot Flaa, Arne Strand
1Department of Cardiology, Ullevaal University Hospital, N-0407 Oslo, Norway. TonjeAmb.Aksnes@ulleval.no
Insights
Antihypertensive medications, particularly those blocking the renin-angiotensin system (RAS), may help prevent new cases of atrial fibrillation (AF) in hypertensive patients. This primary prevention strategy shows promise beyond simply lowering blood pressure.
Area of Science:
- Cardiology
- Hypertension Research
- Preventive Medicine
Background:
- Hypertension significantly elevates the risk of developing atrial fibrillation (AF), contributing to increased cardiovascular morbidity and mortality.
- Traditional AF management focused on rate/rhythm control and preventing adverse outcomes, not primary prevention.
- Emerging strategies explore primary prevention of AF in at-risk populations.
Purpose of the Study:
- To review the potential of antihypertensive treatments in preventing new-onset atrial fibrillation (AF).
- To specifically examine the role of renin-angiotensin system (RAS) blockers in AF prevention.
- To synthesize findings from recent clinical trials and secondary analyses.
Main Methods:
- Review of recent randomized trials concerning hypertension and heart failure.
- Analysis of secondary data from large-scale clinical studies.
- Inclusion of prospective studies investigating AF recurrence prevention with RAS blockade.
Main Results:
- Secondary analyses of hypertension and heart failure trials suggest antihypertensive treatments offer benefits beyond blood pressure reduction.
- Evidence indicates potential preventive effects of RAS blockers on new-onset AF.
- Some prospective studies support RAS blockade for preventing AF recurrence.
Conclusions:
- Antihypertensive therapy, especially RAS blockade, shows promise for the primary prevention of atrial fibrillation in hypertensive individuals.
- Further research and prospective studies are anticipated to solidify the role of these treatments in AF prevention.
- This review highlights a shift towards primary prevention strategies for AF in the context of hypertension management.
Abstract:
Hypertensive patients have an increased risk of developing atrial fibrillation (AF), which increases cardiovascular morbidity and mortality in this population. Primary prevention is a new strategy in treating AF; previously, it was more common to focus on preventing adverse outcomes and controlling the arrhythmia's rate and rhythm. In this review, we consider the possible preventive effects of antihypertensive treatment on new-onset AF seen in recent trials, especially with blockers of the renin-angiotensin system (RAS). Several secondary analyses of large, randomized trials regarding hypertension and heart failure have shown promising results with benefits beyond the expected blood pressure-lowering effect. A few prospective studies on prevention of AF recurrence with RAS blockade have been published, and more studies are expected to be published in the near future.
Related Concept Videos
Hypertension IV: Drug Therapy and Lifestyle Modifications
Atherosclerosis III: Management
Dysrhythmias VI: Management of Dysrhythmias
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Direct Renin Inhibitors
Hypertension V: Nursing Management
